CAR T-cell therapy

March 12, 2019

Cell Medica Earns $8.7 Million Grant to Accelerate Off-the-shelf CAR-NKT Cell Therapy

News

Aiming to support the development of CMD-502, a new cell-based therapy that uses donor-derived natural killer T-cells to fight cancer, the Cancer Prevention and Research Institute of Texas (CPRIT) has awarded Cell Medica an $8.7 ... Read more

February 26, 2019

Yescarta Approved in Canada for Adults with Relapsed or Refractory Large B-cell Lymphoma

News

Health Canada has approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with diffuse large B-cell lymphoma (DLBCL) who have already received two or more lines of systemic therapy. Specifically, ... Read more

February 13, 2019February 14, 2019

Stand Up To Cancer’s ‘Dream Team’ to Investigate Devimistat Combo Therapy for T-cell Lymphoma

News

Rafael Pharmaceuticals‘ devimistat (CPI-613) — which targets the metabolic alterations in cancer cells — will be studied as part of a combination therapy for the treatment of T-cell lymphoma, the company announced. ... Read more

February 12, 2019

Experts Propose New Consensus Scale for CAR T-cell Therapy Toxicities

News

The American Society for Blood and Marrow Transplantation (ASBMT) proposed a new consensus scale for toxicities associated with CAR T-cell therapies to better categorize their severity in both the hospital setting ... Read more

February 8, 2019

U.K. Institute Recommends Kymriah for Adults with Aggressive DLBCL

News

The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended that Kymriah (tisagenlecleucel) be offered to patients with difficult-to-treat diffuse large B-cell lymphoma (DLBCL) through the Cancer Drugs Fund. Specifically, this Novartis-developed therapy ... Read more

February 8, 2019February 5, 2019

The Joy of a New Oncologist

Columns, Things That Give Me Hope - a Column by Bob McEachern

I seem to have bad luck with oncologists. I was diagnosed with follicular lymphoma a little over 11 years ago. But in the last five years, I have had five ... Read more

February 7, 2019February 14, 2019

Stand Up To Cancer’s ‘Dream Team’ of Experts Working on New Therapies for T-cell Lymphoma

News

Stand Up To Cancer (SU2C) has put together an $8 million “dream team” of expert scientists who will focus on discovering new treatments for T-cell lymphoma based on CAR T-cell immunotherapy. ... Read more

February 1, 2019February 1, 2019

Allogene’s Donor-derived CAR T-cell Therapy Cleared for Clinical Testing on Non-Hodgkin’s Lymphoma

News

Allogene Therapeutics and its partner Servier will soon launch a Phase 1/2 trial to assess the investigational cell therapy ALLO-501 in non-Hodgkin’s lymphoma patients who failed prior therapies, after the U.S. Food and Drug ... Read more

December 18, 2018

Depleting White Blood Cells Improves Response to CAR T-cell Therapy in Heavily Treated Patients, Trial Shows

News

A preconditioning chemotherapy regimen given before CD30.CAR-T therapy — a CAR T-cell therapy directed at CD30-positive cancers — seems to improve heavily treated lymphoma patients’ responses to the treatment, a Phase 1/2 ... Read more

November 28, 2018December 1, 2018

Leukemia & Lymphoma Society Funding Next Wave of Blood Cancer Research

News

The Leukemia & Lymphoma Society (LLS) has announced $42 million in new grants for 80 disease research teams globally, in its continuing efforts to invest in comprehensive blood cancer research. More ... Read more